Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Bezisterim · NE-3107, HE-3286

Small molecule · developed by BioVie

Phase 3 Most advanced trial (none active)

BIVI Developer

1 Registered trials

What is Bezisterim?

Bezisterim (NE3107) is an orally bioavailable, blood-brain barrier permeable small molecule with anti-inflammatory properties. It targets multiple mechanisms of pathology in Alzheimer's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: NE-3107, HE-3286
Drug type: Small molecule
Therapy area: Neurology
Developer: BioVie Inc. (BIVI)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: PH8858757I

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04669028	Phase 3	Alzheimer Disease	Completed	BIVI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer Disease

More from BioVie

BIV201 Phase 2

Sources

ClinicalTrials.gov NCT04669028

Updated Oct 3, 2026. Something wrong or missing? Report it on the BIVI page.

Follow BIVI, the company behind Bezisterim

See BIVI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIVI catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z